Clinical trials: Cervical Intraepithelial Neoplasia (CIN)
CIN 2/3, HPV Infection
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).
- Conditions
- CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia
- Trial name
- ART-CIN_IIB (NCT04098744)
- Testing
- Artesunate vaginal insert
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- Frantz Viral Therapeutics, LLC
Cervical Cancer, Precancerous Condition
Digital Colposcopy in Finding Cervical Intraepithelial Neoplasia in Patients With An Abnormal Pap Smear
RATIONALE: Diagnostic procedures, such as digital colposcopy, may help doctors find and diagnose cervical intraepithelial neoplasia.
- Trial name
- NCT00610662
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Cervical Intraepithelial Neoplasia, Cervical Cancer
Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine
This is a phase II clinical study of the novel recombinant HPV 16/18 bivalent vaccine expressed in E. coli. The primary purpose of this study is to evaluate which dosage of the HPV vaccine can induce higher antibody and at the…
- Trial name
- NCT01356823
- Testing
- 30μg HPV, 60μg HPV, 90μg HPV
- Where
- China
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Cervical Intraepithelial Neoplasia
A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age
The main purpose of this study was to evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals SA (GSK)'s investigational adjuvanted human papillomavirus (HPV) vaccine formulations.
- Trial name
- NCT05496231
- Testing
- HPV9 High formulation, HPV9 Medium formulation, HPV9 Low formulation
- Where
- 68 sites in United States, Bulgaria and 6 more
- Volunteers
- 1,080 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Infection
A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine
This study is to demonstrate that the administration of the investigational vaccine can reduce the Combined Incidence of HPV types 6/11/16/18/31/33/45/52/58-related high-grade Cervical Intraepithelial Neoplasia (CIN 2/3)…
- Trial name
- NCT05668572
- Testing
- Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）
- Where
- 3 sites in China
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Cervical Intraepithelial Neoplasia
Retrospective Study on the Evolution of CIN 1 to 3 in Per and Postpartum in Nancy From 2014 to 2022
In France, the screening rate for cervical cancer remains too low. Screening is simple and non-invasive. Pregnant patients are most of the time young and are part of the target population for screening, and for many women, it is…
- Trial name
- NCT05595252
- Testing
- cervical biopsy
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Infection, Precancerous Condition
Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
RATIONALE: Vaccines made from human papillomavirus may help the body build an effective immune response to kill HIV cells. PURPOSE: This phase II trial is studying the side effects and how well human papillomavirus vaccine…
- Trial name
- NCT00513526
- Testing
- Gardasil
- Where
- 8 sites in United States
- Volunteers
- 112 people
- Sponsor
- AIDS Malignancy Consortium
Cervical Cancer, Precancerous Condition
Identifying Biomarkers for Early Detection of Cancer in Patients With Cervical Dysplasia or Carcinoma in Situ of the Cervix
RATIONALE: Studying the genes expressed in samples of tissue from patients with abnormal cells may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00601601
- Volunteers
- 80 people
- Sponsor
- British Columbia Cancer Agency
CIN 2/3, HIV Infections
5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa
This is a single arm study on the safety, feasibility, and acceptability of adjuvant, self-administered, intravaginal 5-Fluorouracil (5-FU) following treatment for high-grade cervical precancer (CIN2/3) among women living with…
- Trial name
- NCT05362955
- Testing
- Intravaginal 5-Fluorouracil (5-FU)
- Where
- Kenya
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2
- Trial name
- NCT04712851
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Jonsson Comprehensive Cancer Center
High Grade Cervical Dysplasia, Cervical Cancer
Overlooked Population at Risk for AIN.
The purpose of this study is to determine the possibility and compliance of performing anal Pap smear and Human Papilloma Virus (HPV) DNA testing on women with high grade lower genital tract dysplasia or cervical cancer and…
- Trial name
- NCT01953094
- Testing
- Screening Anal Pap Smear - No High Resolution Anoscopy, Screening Anal Pap Smear - With High Resolution Anoscopy
- Where
- Canada
- Volunteers
- 355 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Urothelial Carcinoma, Melanoma
SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma
The study is an exploratory prospective, single center study with correlative endpoints. The study will investigate the association of tumor cGAS STING signaling with SAbR.
- Conditions
- Urothelial Carcinoma, Melanoma, Cervical Carcinoma in Situ
- Trial name
- NCT02986867
- Testing
- SAbR Treatment of Lesions
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Texas Southwestern Medical Center
Cervical Cancer, Cervical Intraepithelial Neoplasia
Randomized Controlled Trial of Human Papillomavirus Testing in Primary Cervical Cancer Screening
Human papillomavirus (HPV)-based cervical screening is known to increase sensitivity for detection of high-grade cervical intraepithelial neoplasia (CIN).
- Trial name
- SWEDESCREEN (NCT00479375)
- Testing
- Adding Human Papillomavirus testing to organised cervical screening
- Where
- Sweden
- Volunteers
- 12,527 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Papillomavirus Infections
Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3
DNA vaccines, which are small pieces of DNA also known as plasmids, have several advantages over traditional vaccines such as live attenuated virus and recombinant protein-based vaccines.
- Trial name
- NCT00685412
- Testing
- VGX-3100
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 18 people
- Sponsor
- Inovio Pharmaceuticals
Cervical Cancer
Measurement of Digital Colposcopy for Fluorescence Spectroscopy of Cervical Intraepithelial Neoplasia
The overall objective of this study is to identify potential improvements for a noninvasive method of diagnosing dysplasia and neoplasia in the cervix using digital colposcopy for colposcopy for fluorescence spectroscopy.
- Trial name
- NCT00513123
- Testing
- Colposcopy
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Papillomavirus Infections
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.
The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.
- Trial name
- NCT00117884
- Testing
- 851B
- Where
- 23 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Takeda
HPV Infection, Cervix Cancer
Prevention and Screening Towards Elimination of Cervical Cancer
The research project applies the protocol of the World Health Organisation for screening of cervical cancer, with testing of hrHPV as first screening, followed by Visual Inspection of the cervix with Acetic Acid for…
- Conditions
- HPV Infection, Cervix Cancer, Cervical Dysplasia
- Trial name
- PRESCRIP-TEC (NCT05234112)
- Testing
- Community mobilisation for hrHPV self-testing, hrHPV self-testing, Follow-up after testing
- Where
- Uganda
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Cervical Intraepithelial Neoplasia III
Treatment of Cervical Intraepithelial Neoplasia (CIN) Grade III With Non-invasive Physical Plasma
The aim of the prospective, unicenter proof-of-principle study is to investigate the anti-neoplastic effectiveness of NIPP against CIN III lesions.
- Trial name
- ZGynO_CINIII (NCT04753073)
- Testing
- Non-invasive physical plasma
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- University Hospital Tuebingen
Uterine Cervical Dysplasia, Uterine Cervix Cancer
The SAFE Study: Satisfaction and Adherence to Follow-Up With Colposcopy Exams
This study is intended to improve the patient experience of communication of colposcopy results and follow-up recommendations to patients.
- Trial name
- NCT03296566
- Testing
- Patient Liaison
- Where
- Canada
- Volunteers
- 297 people
- Sponsor
- University of British Columbia
Cervical Intraepithelial Neoplasia
Evaluation of Human Papilloma Virus (HPV) Self-testing to Increase Screening Uptake
Cervical cancer is a leading cause of mortality among women in developing countries. A key factor has been the failure to achieve good coverage.
- Trial name
- EMA (NCT02095561)
- Testing
- HPV self testing
- Where
- Argentina
- Volunteers
- 6,013 people
- Sponsor
- Instituto Nacional del Cáncer, Argentina